Authors : Decruyenaere P; Department of Hematology, Ghent University Hospital, 9000 Ghent, Belgium.; OncoRNALab, Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.

Subjects: Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/genetics ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/pathology ; Cyclophosphamide*

Source: International journal of molecular sciences [Int J Mol Sci] 2024 Sep 16; Vol. 25 (18). Date of Electronic Publication: 2024 Sep 16.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Decursin Induces G1 Cell Cycle Arrest and Apoptosis through Reactive Oxygen Species-Mediated Endoplasmic Reticulum Stress in Human Colorectal Cancer Cells in In Vitro and Xenograft Models.

Authors : Kim D; Division of Research Center, Scripps Korea Antibody Institute, Chuncheon 24341, Republic of Korea.; Go SH

Subjects: Endoplasmic Reticulum Stress*/Endoplasmic Reticulum Stress*/Endoplasmic Reticulum Stress*/drug effects ; Reactive Oxygen Species*/Reactive Oxygen Species*/Reactive Oxygen Species*/metabolism ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/metabolism

Source: International journal of molecular sciences [Int J Mol Sci] 2024 Sep 14; Vol. 25 (18). Date of Electronic Publication: 2024 Sep 14.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas.

Authors : Ishikawa K; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.; Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.

Subjects: Hyaluronan Receptors*/Hyaluronan Receptors*/Hyaluronan Receptors*/metabolism ; Hyaluronan Receptors*/Hyaluronan Receptors*/Hyaluronan Receptors*/immunology ; Mouth Neoplasms*/Mouth Neoplasms*/Mouth Neoplasms*/drug therapy

Source: International journal of molecular sciences [Int J Mol Sci] 2024 Aug 24; Vol. 25 (17). Date of Electronic Publication: 2024 Aug 24.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer.

Authors : Naldi L; Pituitary Diseases and Sodium Alterations Unit, AOU Careggi, 50139 Florence, Italy.; Endocrinology, Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, AOU Careggi, 50139 Florence, Italy.

Subjects: Tolvaptan*/Tolvaptan*/Tolvaptan*/pharmacology ; Tolvaptan*/Tolvaptan*/Tolvaptan*/therapeutic use ; Antidiuretic Hormone Receptor Antagonists*/Antidiuretic Hormone Receptor Antagonists*/Antidiuretic Hormone Receptor Antagonists*/pharmacology

Source: International journal of molecular sciences [Int J Mol Sci] 2024 Aug 01; Vol. 25 (15). Date of Electronic Publication: 2024 Aug 01.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic Cancer.

Authors : Basu R; Edison Biotechnology Institute, Ohio University, Athens, OH 45701, USA.; Diabetes Institute, Ohio University, Athens, OH 45701, USA.

Subjects: Gemcitabine* ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/analogs & derivatives ; Deoxycytidine*/Deoxycytidine*/Deoxycytidine*/pharmacology

Source: International journal of molecular sciences [Int J Mol Sci] 2024 Jul 06; Vol. 25 (13). Date of Electronic Publication: 2024 Jul 06.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine.

Authors : Li Y; Division of Technology Convergence, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Gyeonggi-Do, Republic of Korea.; Sung Y

Subjects: Benzimidazoles*/Benzimidazoles*/Benzimidazoles*/pharmacology ; Benzimidazoles*/Benzimidazoles*/Benzimidazoles*/administration & dosage ; Aminopyridines*/Aminopyridines*/Aminopyridines*/pharmacology

Source: International journal of molecular sciences [Int J Mol Sci] 2024 Jul 05; Vol. 25 (13). Date of Electronic Publication: 2024 Jul 05.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Disarib, a Specific BCL2 Inhibitor, Induces Apoptosis in Triple-Negative Breast Cancer Cells and Impedes Tumour Progression in Xenografts by Altering Mitochondria-Associated Processes.

Authors : Manjunath M; Department of Biotechnology and Applied Bioinformatics, Institute of Bioinformatics and Applied Biotechnology, Electronic City Phase 1, Bengaluru 560100, India.; Ravindran F

Subjects: Triple Negative Breast Neoplasms*/Triple Negative Breast Neoplasms*/Triple Negative Breast Neoplasms*/metabolism ; Triple Negative Breast Neoplasms*/Triple Negative Breast Neoplasms*/Triple Negative Breast Neoplasms*/drug therapy ; Triple Negative Breast Neoplasms*/Triple Negative Breast Neoplasms*/Triple Negative Breast Neoplasms*/pathology

Source: International journal of molecular sciences [Int J Mol Sci] 2024 Jun 12; Vol. 25 (12). Date of Electronic Publication: 2024 Jun 12.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy.

Authors : Kim JS; Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul 07061, Republic of Korea.; Kim MY

Subjects: Proto-Oncogene Proteins c-met*/Proto-Oncogene Proteins c-met*/Proto-Oncogene Proteins c-met*/metabolism ; Proto-Oncogene Proteins c-met*/Proto-Oncogene Proteins c-met*/Proto-Oncogene Proteins c-met*/antagonists & inhibitors ; Stomach Neoplasms*/Stomach Neoplasms*/Stomach Neoplasms*/drug therapy

Source: International journal of molecular sciences [Int J Mol Sci] 2024 May 29; Vol. 25 (11). Date of Electronic Publication: 2024 May 29.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.

Authors : Gu X; Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08554, USA.; Majumder J

Subjects: Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/drug therapy ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/metabolism ; Pancreatic Neoplasms*/Pancreatic Neoplasms*/Pancreatic Neoplasms*/pathology

Source: International journal of molecular sciences [Int J Mol Sci] 2024 May 19; Vol. 25 (10). Date of Electronic Publication: 2024 May 19.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models.

Authors : Revia S; Research Unit Oncology, Merck Healthcare KGaA, Darmstadt, Germany.; Neumann F

Subjects: Drug Synergism* ; Topoisomerase II Inhibitors*/Topoisomerase II Inhibitors*/Topoisomerase II Inhibitors*/pharmacology ; Topoisomerase II Inhibitors*/Topoisomerase II Inhibitors*/Topoisomerase II Inhibitors*/therapeutic use

Source: International journal of molecular sciences [Int J Mol Sci] 2024 May 08; Vol. 25 (10). Date of Electronic Publication: 2024 May 08.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Characterizing the Cell-Free Transcriptome in a Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting.

Decursin Induces G1 Cell Cycle Arrest and Apoptosis through Reactive Oxygen Species-Mediated Endoplasmic Reticulum Stress in Human Colorectal Cancer Cells in In Vitro and Xenograft Models.

Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas.

The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer.

Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic Cancer.

Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine.

Disarib, a Specific BCL2 Inhibitor, Induces Apoptosis in Triple-Negative Breast Cancer Cells and Impedes Tumour Progression in Xenografts by Altering Mitochondria-Associated Processes.

Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy.

Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.

Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models.

اتصل بنا

اتبع